Neumora Therapeutics, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On October 26, 2026, Neumora Therapeutics received notice of failure to satisfy continued listing standards, triggering Item 3.01 disclosure. The filing does not specify which exchange, which listing rule was violated, or any remediation plan. This represents a critical corporate governance event for a $63.3M market-cap biotech company.
Why this rating
Delisting notice threatens continued public trading and capital access—existential risk for small-cap biotech dependent on equity markets for funding.
Extracted items
Price action (we called it negative)
before filing · preread $0.37 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.